Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

被引:99
作者
Ayrignac, Xavier [1 ]
Le Bars, Emmanuelle [2 ,3 ,4 ]
Duflos, Claire [5 ]
Hirtz, Christophe [6 ,7 ]
Maceski, Aleksandra Maleska [6 ,7 ]
Carra-Dalliere, Clarisse [1 ]
Charif, Mahmoud [1 ]
Pinna, Frederic [1 ]
Prin, Pauline [1 ]
de Champfleur, Nicolas Menjot [2 ,3 ,4 ]
Deverdun, Jeremy [2 ,3 ,4 ]
Kober, Tobias [8 ,9 ,10 ]
Marechal, Benedicte [8 ,9 ,10 ]
Fartaria, Mario Joao [8 ,9 ,10 ]
Jerez, Ricardo Corredor [8 ,9 ,10 ]
Labauge, Pierre [1 ]
Lehmann, Sylvain [6 ,7 ]
机构
[1] Univ Montpellier, Dept Neurol, CRC Sclerose Plaques, CHU Montpellier,INSERM, 80 Augustin Fliche, F-34295 Montpellier, France
[2] Montpellier Univ Hosp Ctr, Dept Neuroradiol, Montpellier, France
[3] CHRU Montpellier, Inst Imagerie Fonct Humaine, I2FH, Hop Gui Chauliac, Montpellier, France
[4] Univ Montpellier, CNRS, Lab Charles Coulomb, UMR 5221, Montpellier, France
[5] Ctr Hosp Reg Univ Montpellier, Econ Evaluat Unit, Montpellier, France
[6] Ctr Hosp Reg Univ Montpellier, Lab Biochim Proteom Clin, Montpellier, France
[7] Inst Regenerat Med & Biotherapy IRMB INSERM, IRB, Montpellier, France
[8] Siemens Healthcare, Adv Clin Imaging Technol, Lausanne, Switzerland
[9] Univ Lausanne, Lausanne Univ Hosp, Dept Radiol, Lausanne, Switzerland
[10] Ecole Polytech, LTS5, Lausanne, Switzerland
关键词
CEREBROSPINAL-FLUID; NEURONAL MARKERS; NEUROFILAMENT; BIOMARKER; DAMAGE;
D O I
10.1038/s41598-020-67934-2
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from disease progression. The aim of our study was to assess serum glial fibrillary acid protein (s-GFAP) and neurofilament light chain (s-NfL) in a cohort of 129 multiple sclerosis (MS) patients. Eighteen primary progressive multiple sclerosis (PPMS) and 111 relapsing remitting MS (RRMS) were included. We showed that these 2 biomarkers were significantly correlated with each other (R=0.72, p<0.001). Moreover, both biomarkers were higher in PPMS than in RRMS even if multivariate analysis only confirmed this difference for s-GFAP (130.3 +/- 72.8 pg/ml vs 83.4 +/- 41.1 pg/ml, p=0.008). Finally, s-GFAP was correlated with white matter lesion load and inversely correlated with WM and GM volume. Our results seem to confirm the added value of s-GFAP in the context of multiple sclerosis.
引用
收藏
页数:5
相关论文
共 21 条
[1]   Serum GFAP as a biomarker for disease severity in multiple sclerosis [J].
Abdelhak, A. ;
Huss, A. ;
Kassubek, J. ;
Tumani, H. ;
Otto, M. .
SCIENTIFIC REPORTS, 2018, 8
[2]   Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? [J].
Abdelhak, Ahmed ;
Hottenrott, Tilman ;
Morenas-Rodriguez, Estrella ;
Suarez-Calvet, Marc ;
Zettl, Uwe K. ;
Haass, Christian ;
Meuth, Sven G. ;
Rauer, Sebastian ;
Otto, Markus ;
Tumani, Hayrettin ;
Huss, Andre .
FRONTIERS IN NEUROLOGY, 2019, 10
[3]   Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis [J].
Alba Mane-Martinez, M. ;
Olsson, Bob ;
Bau, Laura ;
Matas, Elisabet ;
Cobo-Calvo, Alvaro ;
Andreasson, Ulf ;
Blennow, Kaj ;
Romero-Pinel, Lucia ;
Martinez-Yelamos, Sergio ;
Zetterberg, Henrik .
JOURNAL OF NEUROIMMUNOLOGY, 2016, 299 :112-117
[4]   Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis [J].
Barro, Christian ;
Benkert, Pascal ;
Disanto, Giulio ;
Tsagkas, Charidimos ;
Amann, Michael ;
Naegelin, Yvonne ;
Leppert, David ;
Gobbi, Claudio ;
Granziera, Cristina ;
Yaldizli, Ozgur ;
Michalak, Zuzanna ;
Wuerfel, Jens ;
Kappos, Ludwig ;
Parmar, Katrin ;
Kuhle, Jens .
BRAIN, 2018, 141 :2382-2391
[5]   Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS [J].
Bergman, Joakim ;
Dring, Ann ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Norgren, Niklas ;
Gilthorpe, Jonathan ;
Bergenheim, Tommy ;
Svenningsson, Anders .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (05)
[6]   Assessing tissue damage in multiple sclerosis: a biomarker approach [J].
Burman, J. ;
Zetterberg, H. ;
Fransson, M. ;
Loskog, A. Sl ;
Raininko, R. ;
Fagius, J. .
ACTA NEUROLOGICA SCANDINAVICA, 2014, 130 (02) :81-89
[7]   Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years [J].
Canto, Ester ;
Barro, Christian ;
Zhao, Chao ;
Caillier, Stacy J. ;
Michalak, Zuzanna ;
Bove, Riley ;
Tomic, Davorka ;
Santaniello, Adam ;
Haering, Dieter A. ;
Hollenbach, Jill ;
Henry, Roland G. ;
Cree, Bruce A. C. ;
Kappos, Ludwig ;
Leppert, David ;
Hauser, Stephen L. ;
Benkert, Pascal ;
Oksenberg, Jorge R. ;
Kuhle, Jens .
JAMA NEUROLOGY, 2019, 76 (11) :1359-1366
[8]   Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis [J].
Disanto, Giulio ;
Barro, Christian ;
Benkert, Pascal ;
Naegelin, Yvonne ;
Schadelin, Sabine ;
Giardiello, Antonella ;
Zecca, Chiara ;
Blennow, Kaj ;
Zetterberg, Henrik ;
Leppert, David ;
Kappos, Ludwig ;
Gobbi, Claudio ;
Kuhle, Jens .
ANNALS OF NEUROLOGY, 2017, 81 (06) :857-870
[9]   Science is 1% inspiration and 99% biomarkers [J].
Dubuisson, Nicolas ;
Puentes, Fabiola ;
Giovannoni, Gavin ;
Gnanapavan, Sharmilee .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (11) :1442-1452
[10]   Partial volume-aware assessment of multiple sclerosis lesions [J].
Fartaria, Mario Joao ;
Todea, Alexandra ;
Kober, Tobias ;
O'brien, Kieran ;
Krueger, Gunnar ;
Meuli, Reto ;
Granziera, Cristina ;
Roche, Alexis ;
Cuadra, Meritxell Bach .
NEUROIMAGE-CLINICAL, 2018, 18 :245-253